Cediranib Maleate

Drug Overview

The medication cediranib maleate is a highly specialized medical treatment currently being studied for cancer care. It belongs to an advanced class of medicines known as Targeted Therapy. Instead of attacking all fast-growing cells like traditional chemotherapy, it specifically targets the blood supply that tumors need to survive.

Here are the key details about this medication:

• Generic Name: cediranib maleate (Pronounced: seh-DEER-uh-nib MAY-lee-AYT).
• US Brand Names: Recentin (also known in research by its code name, AZD2171).
• Drug Class: Antiangiogenesis Agent / Vascular Endothelial Growth Factor (VEGF) Receptor Tyrosine Kinase Inhibitor.
• Route of Administration: Oral (PO) tablet.
• FDA Approval Status: Currently investigational. It is not yet FDA-approved for standard public use, but it is actively studied in advanced clinical trials around the world.

What Is It and How Does It Work? (Mechanism of Action)

To grow and spread, a tumor needs a constant supply of oxygen and nutrients. To get this, the tumor sends out chemical signals that force the body to build new blood vessels directly into the cancer mass. This process of building new blood vessels is called angiogenesis.

Cediranib maleate is a powerful Targeted Therapy designed to stop this process. Here is how it works at the molecular level:

1. Blocking the Antennas: On the surface of blood vessel cells, there are special protein “antennas” called Vascular Endothelial Growth Factor Receptors (VEGFR-1, -2, and 3) and Platelet-Derived Growth Factor Receptors (PDGFR). Tumors send signals to these antennas to trigger the growth of new blood vessels.
2. The Chemical Roadblock: Cediranib acts as a roadblock. It enters the cell and competes with the body’s natural energy source (ATP) to bind to these receptor enzymes (tyrosine kinases).
3. Shutting Down the Signal: By locking onto these receptors, cediranib completely blocks the signaling pathways (such as the Raf/MEK/ERK pathways) inside the cell.
4. Starving the Tumor: Because the signals are blocked, the blood vessels stop growing. Existing blood vessels feeding the tumor may also shrink or break down. Without a blood supply, the cancer cells starve, stop growing, and eventually die.

FDA-Approved Clinical Indications

Because cediranib maleate is an investigational agent, it does not currently have official FDA-approved indications for routine clinical practice. However, it is being extensively studied in clinical trials for the following purposes:

• Oncological Uses (In Clinical Trials):
  • Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: Often used in combination with other targeted drugs for patients whose cancer has returned after earlier treatments.
  • Endometrial Cancer: Used for advanced or recurrent cancer of the uterus lining.
  • Soft Tissue Sarcomas: Specifically studied for a rare type of cancer called alveolar soft part sarcoma that has spread to other parts of the body.
• Non-oncological Uses:
  • There are currently no standard non-oncological uses for this medication; its research is strictly focused on cancer care.

Dosage and Administration Protocols

Because this is an oral targeted therapy, it is taken as a pill rather than infused through an IV.

Clinical Efficacy and Research Results

Recent clinical studies (between 2020 and 2025) highlight the potential of cediranib, especially when combined with other smart drugs like PARP inhibitors (such as olaparib).

• Ovarian Cancer Trials (CONCERTO Trial, 2022): In a trial involving heavily pre-treated patients with platinum-resistant ovarian cancer, the combination of cediranib and olaparib showed an Objective Response Rate (tumor shrinkage) of 15.3%. Patients had a median Progression-Free Survival (time before the cancer started growing again) of 5.1 months, and an Overall Survival of 13.2 months.
• Endometrial Cancer Trials (NRG-GY012 Trial, 2024): In patients with advanced endometrial cancer, the median Progression-Free Survival for patients taking cediranib alone was 3.8 months. When combined with olaparib, this increased to 5.5 months, showing that combining therapies can improve results for difficult-to-treat cancers.

Safety Profile and Side Effects

While cediranib does not cause the same side effects as traditional chemotherapy (like severe hair loss), blocking blood vessel growth affects normal blood vessels, too.

Black Box Warning: Because it is an investigational drug, there is no official FDA Black Box Warning yet. However, drugs in this class carry strict warnings for severe heart and blood vessel problems.

Common Side Effects (>10%)

• High Blood Pressure (Hypertension): Very common (affecting up to 36% of patients in some trials) because narrowing blood vessels increases pressure.
• Fatigue: Feeling very tired or weak.
• Gastrointestinal Issues: Diarrhea and nausea are frequently reported.
• Protein in the Urine (Proteinuria): A sign that the drug is irritating the tiny blood vessels in the kidneys.

Serious Adverse Events

• Heart Rhythm Changes: The drug can cause “QTc prolongation,” which is an irregular heartbeat that can be dangerous.
• Vascular Dysfunction: In rare cases, it can cause tiny blood clots or issues with the heart’s pumping function.

Management Strategies

• If blood pressure spikes, the medical team will prescribe standard blood pressure medications.
• Patients will have routine heart scans (ECGs) to monitor heart rhythms. If an irregular heartbeat is found, the drug may be paused.
• Frequent urine tests are done to check kidney health. If protein levels get too high, the doctor will lower the drug dose.

Research Areas

Cediranib has a fascinating connection to the future of Immunotherapy and combined Targeted Therapy. Scientists have discovered that when cediranib cuts off the blood supply, it creates a “hypoxic” (low-oxygen) environment inside the tumor. This stress forces the tumor to turn off its own DNA repair mechanisms. By making the tumor terrible at fixing its own DNA, doctors can then introduce a second drug, a PARP inhibitor like olaparib, which destroys the cancer cells entirely. Researchers are also exploring how cutting off abnormal tumor blood vessels might help the body’s immune system fight the cancer more effectively when combined with immune checkpoint inhibitors.

Patient Management and Practical Recommendations

To ensure the highest safety and best results, patients must follow specific guidelines while taking cediranib.

Pre-treatment Tests to be Performed:

• Blood Pressure Check: A baseline reading to ensure blood pressure is well-controlled before starting.
• Heart Scans: An Electrocardiogram (ECG) and an ultrasound of the heart (ECHO/MUGA scan) to check for a healthy heart rhythm.
• Urine and Blood Tests: To check baseline kidney and liver health.
• Pregnancy Test: A strict requirement for women of childbearing age, as stopping blood vessel growth can severely harm an unborn baby.

Precautions During Treatment:

• You must monitor your blood pressure daily at home.
• Inform your doctor immediately if you feel dizzy, experience a racing heartbeat, or have severe, unstoppable diarrhea.

“Do’s and Don’ts” List:

• DO take your pill at the same time every day to keep a steady amount of medicine in your body.
• DO keep a daily log of your home blood pressure readings to share with your nurse or doctor.
• DON’T get pregnant or father a child while on this medication. Use highly effective birth control during treatment and for several months after the last dose.
• DON’T start any new medications, over-the-counter drugs, or herbal supplements without asking your oncologist, as they might affect your heart rhythm.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Cediranib maleate is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.